CN105816479B - A kind of preparation method of ergosterol combination with cisplatin Active loading liposome - Google Patents
A kind of preparation method of ergosterol combination with cisplatin Active loading liposome Download PDFInfo
- Publication number
- CN105816479B CN105816479B CN201610141194.6A CN201610141194A CN105816479B CN 105816479 B CN105816479 B CN 105816479B CN 201610141194 A CN201610141194 A CN 201610141194A CN 105816479 B CN105816479 B CN 105816479B
- Authority
- CN
- China
- Prior art keywords
- ergosterol
- liposome
- preparation
- platinum
- cis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a kind of preparation method of ergosterol combination with cisplatin Active loading liposome, main process is：Ergosterol liposome preparation and ammonium chloride gradient form, carry medicine.Present invention process is simple and practicable, and the encapsulation rate of drug is high, and effect is played instead of cis-platinum using ergosterol part, gained ergosterol combination with cisplatin Active loading liposome is while ensureing anti-lung cancer effect, the toxic side effect that can significantly reduce drug, it is small to the injury of human body, there is targeting.
Description
Technical field
Lung-cancer medicament is treated the present invention relates to a kind of, more particularly to a kind of ergosterol combination with cisplatin Active loading liposome
Preparation method.
Background technology
The chemical compositions such as polysaccharide, triterpene compound, protein, vitamin, trace element are mainly contained in Antrodia camphorata, separately
Outside, also super oxygen dismutase (SOD), adenosine, nucleic acid, agglutinin, amino acid, steroid, lignin, blood pressure stabilization substance etc..
Triterpene compound is considered as one of the main source of Antrodia camphorata bitter taste, is present in mycelium and fructification.To being at present
Only, it was found that nearly 30 kinds of triterpene compounds, predominantly two big precursor structure of lanostane and lumistane.
It is to be still drank after a night and treat liver disease for alleviating that Antrodia camphorata is eaten by people earliest, is also widely studied in recent years, into
One step confirms Antrodia camphorata anti-liver cancer and anti-, hepatoprotective effect.Another hot spot of Antrodia camphorata research is the antitumor of Antrodia camphorata
Effect, further includes breast cancer, colon cancer, carcinoma of mouth etc. in addition to liver cancer.Xu Tai is great et al. to the Taiwan 1992-2010 antrodia phase
The rich papers of Guan Shuo have carried out summary analysis and have found, can be divided into 24 classes, preceding 5 class of most study to the bioactivity research of Antrodia camphorata
It is ordered as successively：(1) antitumor, (2) liver protection, (3) are anti-oxidant, (4) immunological regulation, (5) anti-inflammatory, it is shown that Antrodia camphorata is main
Pharmacological activity, live in addition, Antrodia camphorata also shows certain pharmacology to cardiovascular and cerebrovascular disease, hypoglycemic, reducing blood lipid etc.
Property.Although the prior art, which reports Antrodia camphorata, not to find its tool with anti-liver cancer and anti-, breast cancer, colon cancer, carcinoma of mouth etc.
There is good effect of anti-lung cancer, although in addition, cognition has antitumaous effect to Antrodia camphorata, due to Antrodia camphorata complicated component,
People are not clear, and which kind of specific ingredient is playing targetedly antitumaous effect, this greatly hinders the research of anticancer drug.
Cis-platinum (CDDP) is the complex compound of a heavy metal species platinum, is difunctional alkylating agent, and chemistry is entitled：Cis--dichloro
Diamino platinum (II) crystallizes, in water slightly soluble for yellow powder, insoluble in common organic solvents such as ethyl alcohol, is dissolved in dimethyl methyl
Amide.It was synthesized in 1845 by M.Peyrone for the first time, and U.S. FDA in 1978 ratifies it and is used for clinical anticancer.Cis-platinum
It was found that having driven metal complex in the development of medical domain, there is revolutionary meaning for treatment of cancer.Its antitumaous effect
Feature has：(1) it is the antineoplastic of high-efficiency broad spectrum, CDDP-DNA compounds can be formed with action target spot DNA and played a role, belonged to
Cell cycle nonspecific agent (CCNSA).It is 61%~98% to tumor control rate, especially not very to solid tumor and to general chemotherapeutic
Sensitive tumor efficiency is more notable；(2) can not only killing tumor cell, inhibit cell repair, also have stronger radiotherapy increase
Quick effect；(3) there is synergistic effect with a variety of antitumor drugs, toxicity spectrum is also different with them, and without cross resistance, because
This easily with other antineoplastic compatibilities, not only improves clinical drug combination, the toxicity of also reversible combined chemotherapy.Therefore, long
Cis-platinum status in anticarcinogen is notable since phase.
But cisplatin formulations used in current clinic, the injections recorded such as Chinese Pharmacopoeia 2010 editions and European Pharmacopoeia 2001
Cis-platinum, 2000 editions cisplatin for injection recorded of British Pharmacopoeia and cis-platinum injections agent are to cancerous tissue, cancer cell without selectivity
Normal injection agent, the bioavilability of drug is low, and toxic side effect is big.Its there are the problem of be mainly shown as：(1) serious poison is secondary
Effect：Cis-platinum and its metabolite are mainly from kidney excretion, therefore renal toxicity is big.Separately there are gastrointestinal toxicity, ototoxicity and Nervous toxicity
Property etc. is also very important；(2) relatively low to certain tumor cell viabilities, such as breast cancer, colon cancer；(3) it is also easy to produce drug resistance；(4)
It is only very slightly soluble in water, property is unstable, decomposes in light, and aqueous solution can occur to hydrolyze and fail after placing at room temperature, and change
For the toxic but anti-platinum without tumor-inhibiting action.
How it is in first of all kinds of cancers in view of lung cancer morbidity rate, the death rate in recent years, and ratio still is continuing to increase
The problem of reducing the toxic side effect of cis-platinum becomes urgent need to resolve.
Invention content
The purpose of the present invention is to provide a kind of preparation methods of ergosterol combination with cisplatin Active loading liposome, use
Ergosterol part plays effect instead of cis-platinum, and gained ergosterol combination with cisplatin Active loading liposome is ensureing anti-lung cancer effect
While fruit, the toxic side effect of drug is can significantly reduce, it is small to the injury of human body, there is targeting.
The technical solution adopted by the present invention to solve the technical problems is：
A kind of preparation method of ergosterol combination with cisplatin Active loading liposome, includes the following steps：
(1) ergosterol liposome preparation：Lecithin, cholesterol, ergosterol are weighed, chloroform dissolving is added, rotation is steamed
Film is sent out into, is dried in vacuo, is that hydrating fluid carries out aquation, ultrasonic demoulding, probe supersound process, mistake under ice bath using ammonium chloride solution
Filter, high pressure squeeze out to obtain ergosterol liposome；
(2) ammonium chloride gradient is formed：The dialysis that molecular cut off is 8000-14000Da is added in ergosterol liposome
In bag, bag filter is closed, puts into distilled water the 2h that dialyses, replaces first water, continues the 2h that dialyses；
(3) medicine is carried：Cis-platinum is mixed and made into cisplatin solution with water, and the ergosterol liposome after previous step is dialysed is added suitable
Platinum solution is incubated, and the addition of ergosterol liposome is to meet the mass ratio of ergosterol and cis-platinum for 1:1-4:1 meter
It calculates, 40-60 DEG C of incubation temperature, incubation time 5-40min obtains product after incubation.
Inventor, which passes through, to study for a long period of time, has been surprisingly found that ergosterol has apparent effect of anti-lung cancer, and cytotoxicity is low,
It is small to the injury of human body.And simple ergosterol can not effectively go directly lesion after entering human body, therefore, by ergosterol
It is encapsulated in liposome, lesion can be reached and play effect, the targeting of liposome so that ergosterol can more preferably play anti-lung
Cancer acts on.Although cis-platinum anticancer effect is preferable, it is there are great toxic side effect, which greatly limits the application of cis-platinum,
Ergosterol is naturally occurring compound in plant, and cytotoxicity is small, and the present invention has preferable anticancer effect using new discovery
And the ergosterol part of hypotoxicity replaces cis-platinum, combination with cisplatin collaboration plays a role, and while ensureing anti-lung cancer effect, shows
Writing reduces the toxic side effect of drug, small to the injury of human body, and has targeting.
Step (1) is encapsulated as hydrating fluid by aquation when cisplatin solution, it is found that its encapsulation rate is less than 10%, explanation
Unsuitable this drug of encapsulating cis-platinum of film dispersion method.Cis-platinum is weakly basic drugs, and the present invention is prepared using ammonium chloride gradient method,
Encapsulation rate can reach 50% or more.
Ammonium chloride gradient method prepares Active loading liposome, and main process is：Ergosterol liposome preparation and ammonium chloride
Gradient forms, carries medicine.Wherein, ammonium chloride gradient is formed most important.Its basic principle is that certain density ammonium chloride is wrapped in fat
Plastid inner aqueous phase removes the ammonium chloride of outer aqueous phase by dialysis.Under the promotion of interior extracellular concentration difference, due to the diffusion system of amino molecule
Number is gradually protonated with the diffusion of amino molecule in liposome much larger than ammonium chloride, to indirectly form pH by ammonium chloride gradient
Gradient.Under this gradient, cis-platinum exists in outer aqueous phase with molecular state, and cross-film ability is strong, is deposited with ionization state in inner aqueous phase
, it is difficult to it spreads, to form stable encapsulated condition.
Preferably, in step (1) raw material components of ergosterol liposome matched in terms of summation 100% it is as follows：Ergot
Sterol 5-20wt%, surplus are lecithin and cholesterol, and the molar ratio of lecithin and cholesterol is 1:1-7:1.
Preferably, in step (1) raw material components of ergosterol liposome matched in terms of summation 100% it is as follows：Ergot
Sterol 8-15wt%, surplus are lecithin and cholesterol, and the molar ratio of lecithin and cholesterol is 3:1-6:1.
Preferably, in step (1) raw material components of ergosterol liposome matched in terms of summation 100% it is as follows：Ergot
Sterol 10wt%, surplus are lecithin and cholesterol, and the molar ratio of lecithin and cholesterol is 5:1.
Preferably, the parameter that Probe Ultrasonic Searching is handled in step (1) is：Ultrasonic time 20min, ultrasonic 2s stop 1s, ultrasound
Power 900W, the pressure that high pressure squeezes out are 400-500psi.
Preferably, a concentration of 0.03-0.3mg/mL of cisplatin solution described in step (3).
Preferably, a concentration of 0.15mg/mL of cisplatin solution described in step (3).
Preferably, 50 DEG C of incubation temperature, incubation time 10min in step (3).
Preferably, the addition of ergosterol liposome is to meet the mass ratio of ergosterol and cis-platinum in step (3)
It is 2.5:1 calculates.
Preferably, in step (1) ammonium chloride solution a concentration of 0.1-1.5mmolL-1.More preferably, ammonium chloride is molten
A concentration of 0.1-0.5mmolL of liquid-1。
The beneficial effects of the invention are as follows：Simple for process, the encapsulation rate of drug is high, is replaced using ergosterol part suitable
Platinum plays effect, and gained ergosterol combination with cisplatin Active loading liposome can significantly drop while ensureing anti-lung cancer effect
The toxic side effect of low drug, it is small to the injury of human body, there is targeting.
Description of the drawings
Fig. 1 is each liposome transmission electron microscope picture.
Fig. 2 is ergosterol combination with cisplatin Active loading liposome Accumulation dissolution.
Fig. 3 is the MTT test results for 24 hours of bulk pharmaceutical chemicals and liposome, with the ergosterol cis-platinum lipid of identical extension rate
Body group is compared, * * P<0.01.
Specific implementation mode
Below by specific embodiment, and in conjunction with attached drawing, technical scheme of the present invention will be further explained in detail.
In the present invention, if not refering in particular to, used raw material and equipment etc. are commercially available or commonly used in the art.
Method in following embodiments is unless otherwise instructed the conventional method of this field.
Embodiment：
A kind of preparation method of ergosterol combination with cisplatin Active loading liposome, includes the following steps：
(1) ergosterol liposome preparation：Lecithin, cholesterol, ergosterol are weighed, chloroform dissolving is added, rotation is steamed
Film is sent out into, is dried in vacuo, with ammonium chloride solution (a concentration of 0.1-1.5mmolL-1) it is that hydrating fluid carries out aquation, ultrasound is de-
Film is popped one's head under ice bath and is ultrasonically treated, and filtering, high pressure squeezes out to obtain ergosterol liposome；The raw material components of ergosterol liposome
It is matched in terms of summation 100% as follows：Ergosterol 5-20wt%, surplus are lecithin and cholesterol, lecithin and cholesterol
Molar ratio is 1:1-7:1.Probe Ultrasonic Searching processing parameter be：Ultrasonic time 20min, ultrasonic 2s, stop 1s, ultrasonic power 900W,
The pressure that high pressure squeezes out is 400-500psi.
(2) ammonium chloride gradient is formed：The dialysis that molecular cut off is 8000-14000Da is added in ergosterol liposome
In bag, bag filter is closed, puts into distilled water the 2h that dialyses, replaces first water, continues the 2h that dialyses；
(3) medicine is carried：Cis-platinum is mixed and made into cisplatin solution, a concentration of 0.03-0.3mg/mL of cisplatin solution, by upper one with water
Ergosterol liposome after step dialysis is added cisplatin solution and is incubated, and the addition of ergosterol liposome is to meet ergot
The mass ratio of sterol and cis-platinum is 1:1-4:1 calculates, 40-60 DEG C of incubation temperature, incubation time 5-40min, after incubation
To product.
One, the best preparation process of ergosterol liposome
1.1, single factor exploration
1.1.1 lecithin is investigated with cholesterol molar ratio
When ergosterol load medicine 5% has been investigated in this experiment, the ratio (molar ratio) of lecithin and cholesterol, both settings ratio
Example is 1:1、3:1、5:1、7:1, encapsulation rate is respectively 71.59%, 89.15%, 92.58%, 96.62%.The two ratio is
1:When 1, since the ratio of cholesterol is higher, the rigidity reinforced of liposome, and the two is 7:Precipitation is susceptible to when 1, after placement.
1.1.2 the Probe Ultrasonic Searching time is investigated
Film dispersion method (weighs lecithin, cholesterol, ergosterol, chloroform dissolving is added, rotation is steamed after preparing liposome
Film is sent out into, is dried in vacuo, aquation, ultrasonic demoulding), by Probe Ultrasonic Searching by large-sized liposome whole grain at small particle lipid
Body.Influence of the different Probe Ultrasonic Searching times for ergosterol liposome encapsulation has been investigated in this experiment.When Probe Ultrasonic Searching is set
Between be 10min, 20min, 30min, 40min, encapsulation rate is respectively 79.45%, 91.73%, 95.86%, 95.94%.With
Time increase, encapsulation rate increases therewith, and encapsulation rate no longer changes when 30min, and Probe Ultrasonic Searching overlong time, is easy to cause fat
Plastid ruptures.
1.1.3 ergosterol drugloading rate is investigated
Influence of the different ergosterol drugloading rates to encapsulation rate has been investigated in this experiment.Ergosterol drugloading rate be 5%,
10%, 15%, 20%, encapsulation rate is respectively 90.76%, 85.81%, 69.79%, 73.09%.
1.2 response surface experiments
1.2.1 Star point design
Single factor experiment the result shows that lecithin and 3 cholesterol ratio, Probe Ultrasonic Searching time and drugloading rate factors to wheat
Angle sterol encapsulation rate, which has, to be significantly affected.According to Star point design principle, lecithin and cholesterol ratio, Probe Ultrasonic Searching time are selected
It is independent variable with drugloading rate, each independent variable determines 3 levels, uses code -1,0 respectively, and 1 indicates, totally 15 testing sites (3
Central point).Each test parallel 3 progress.Using ergosterol liposome encapsulation as evaluation index, using Star point design (table
1) preferred preparation process condition.
1 ergosterol liposome preparation technique asterism test arrangement (n=3) of table
1.2.2 the foundation and variance analysis of model
Secondary multiple regression fitting is carried out to data in table with Design-Expert.V 8.0.6.1 softwares, derives from and becomes
Regression equation Y=90.40+17.87X between amount and dependent variable1- 2.58X2+4.14X3- 7.62X1X2+6.28X1X3+
3.03X2X3- 21.95X1 2- 4.29X2 2- 2.44X3 2.Significance test is carried out to the regression model.Table 2 is the result shows that X1, X1 2
It is extremely notable to the linear effect of response, X2, X3, X2 2It is notable to the curved surface effect effect of response, interaction item X1X2、X1X3Effect
Significantly.The F=82.84 of the model, P ＜ 0.000 1 shows that the secondary multivariate regression models is extremely notable, regression equation phase relation
Number (r) 0.9967, illustrates that model can explain that the variation of 99.67% response, fit solution are good.
2 regression model variance analysis of table
1.2.3 response surface analysis
According to regression equation, when it is 0 to keep 1 factor encoded radio, with Design-Expert.V8.0.6.1 softwares
Draw the three-dimensional response surface figure of another 2 factors and ergosterol encapsulation rate relationship.Response surface is response to interaction factor two-by-two
The three-dimensional space curve figure constituted, effect surface curve is more precipitous, illustrates that influence of each independent variable to response is more apparent.It fetches
Return model maximum of points, corresponding measured value is lecithin and cholesterol ratio is 5:1, the Probe Ultrasonic Searching time is 20min, ergot
Sterol drugloading rate is 10%.
1.2.4 verification test
To verify the applicability of model equation, precision weighs lecithin 98mg, cholesterol 10mg, ergosterol 12mg, and totally 3
Part, verification test is carried out by following the best conditions of preparation pr ocess, as a result the average value of 3 batches of liposome encapsulations is 90.49%,
RSD 2.64%, and predicted value 90.40% deviation 0.10%, show establish mathematical model have good predictability, it is excellent
The process conditions of choosing are reproducible.
The best preparation process of ergosterol liposome is：Lecithin and cholesterol molar ratio 5:1, ergosterol carries medicine
10%, Probe Ultrasonic Searching 20min.
Concrete technology condition：Lecithin 98mg, cholesterol 10mg and ergosterol 12mg, are fully dissolved with 10mL chloroforms
Afterwards, it is placed on the Rotary Evaporators of 40 DEG C of water-baths and is spin-dried for, be dried in vacuo 2h, 10mL ammonium chloride solutions (0.5mmolL is added-1)
It is placed in aquation 30min on horizontal shaker, rotating speed 140rpmmL at room temperature-1.After aquation, ultrasonic demoulding places liposome
Under ice bath, Probe Ultrasonic Searching 20min, ultrasonic 2s stop 1s, ultrasonic power 900W.Successively use 0.8 μm, 0.45 μm, 0.22 μm it is micro-
Hole membrane filtration, finally with 0.1 μm of polycarbonate membrane high pressure squeeze out (pressure 400-500psi) to get.
Two, the best preparation process of ergosterol combination with cisplatin Active loading liposome investigates
2.1 single factor experiment
2.1.1 the investigation of ergosterol/cis-platinum mass ratio
The mass ratio of ergosterol and cis-platinum has been investigated in this experiment, is equivalent to drugloading rate of the cis-platinum in liposome, is pressed
1.2.4 after preparing optimised process ergosterol liposome, it is 8000- that molecular cut off, which is added, in ergosterol liposome
In the bag filter of 14000Da, bag filter is closed, puts into distilled water the 2h that dialyses, replaces a dialyzate (distilled water), is continued saturating
Analyse 2h.It mixes and is incubated with various concentration cisplatin solution by ergosterol liposome, the mass ratio that the two is arranged is 0.313:
1、0.625:1、1.25:1、2.5:1、5:1, as a result display is 2.5 when the mass ratio of ergosterol and cis-platinum:When 1, the packet of cis-platinum
Envelope rate is maximum, reaches 35.33%.
2.1.2 the investigation of incubation time
This experiment investigated cisplatin solution incubation time be respectively 5,10,20,40min when encapsulation rate, as a result display works as
When incubation time is 20min, cis-platinum encapsulation rate is maximum, and 31.07%.
2.1.3 the investigation of incubation temperature
40,50,60, the 80 DEG C of influences of temperature for cis-platinum encapsulation rate have been investigated in this experiment, as a result show 50 DEG C and 80 DEG C
When encapsulation rate it is maximum, but excessively high temperature can cause lecithin that oxidation occurs and generates hemolytic.
2.2 orthogonal test
On the basis of single factor experiment is investigated, ergosterol combination with cisplatin is optimized using Three factors-levels orthogonal design
Active loading liposome selects L9(34) orthogonal arrage arrangement experiment.Select 3 incubation time, incubation temperature, cis-platin concentrations factors
Best ergosterol combination with cisplatin Active loading liposome preparation technique is determined as investigation factor.Orthogonal design factor level table
See, positive quadraturing design test scheme and analysis of experimental results are shown in Table 3, table 4.
3 L of table9(34) orthogonal arrage
4 L of table9(34) planning of experiments table
Using the extremum difference analysis of single index positive quadraturing design test result.The result shows that：Each factor is to cis-platinum encapsulation rate
Influence degree is C>A>B, optimal combination are that ergosterol combination with cisplatin Active loading liposome optimised process is A1B3C1, i.e., suitable
Platinum concentration is 0.150mgmL-1, 70 DEG C of incubation temperature, incubation time 10min.The phase for being located at soybean lecithin in view of 70 DEG C
More than temperature, and the influence of incubation temperature this factor to encapsulation rate is little, therefore optimised process is adjusted to cis-platin concentrations
For 0.150mgmL-1, 50 DEG C, incubation time 10min of incubation temperature, to adjustment, front and back optimised process is verified.
2.3 orthogonal tests are verified
3 batches of ergosterol combination with cisplatin Active loadings are prepared respectively by optimised process after orthogonal test optimised process and adjustment
Liposome is measured cis-platinum encapsulation rate, average grain diameter, Zeta potential by ultrafiltration.3 batches of liposomes are averaged encapsulation rate knot
Fruit is respectively 49.04% and 52.24%.Table 5, table 6 the result shows that, it is the encapsulation rate of optimised process after optimised process and adjustment, flat
Equal grain size, Zeta potential there are no significant difference, therefore, subsequent experimental is using optimised process, i.e. cis-platin concentrations after adjustment
0.150mg·mL-1, 50 DEG C of incubation temperature, the system of incubation time 10min progress ergosterol combination with cisplatin Active loading liposomes
It is standby.
5 optimised process verification result of table
Optimised process verification result after table 6 adjusts
Three, ergosterol combination with cisplatin Active loading liposome quality evaluation
3.1 morphologic observation
3.1.1 mode of appearance
Ergosterol combination with cisplatin Active loading liposome solutions are creamy white, uniform color.
3.1.2 microscopic morphology
Sample is prepared using negative staining.At ambient temperature, ergosterol combination with cisplatin Active loading liposome is taken, is distilled
Water, which is diluted to, shows slightly muddy, drops on special 230 mesh copper mesh, filter paper blots extra liposome, stands 1min.With 1% phosphotungstic acid
Negative staining stands 40s, makes particle in copper deposited thereon, draws the extra dye liquor in copper mesh edge with filter paper, volatilizes naturally, Electronic Speculum observation
And it takes a picture.Fig. 1's the result shows that, each liposome rounding, particle diameter distribution is uniform.
3.1.3 encapsulation rate and drugloading rate
In 3 batches of ergosterol combination with cisplatin Active loading liposomes, the average encapsulation rate of wherein ergosterol is
90.49%, drugloading rate 0.1401mgmL-1；The average encapsulation rate of cis-platinum is 52.24%, drugloading rate 0.1382mgmL-1。
3.1.4 particles size and distribution
Under room temperature, ergosterol combination with cisplatin Active loading liposome is taken, dilutes 20 times, injects sample cell, laser
Particle size analyzer determination average grain diameter and its distribution.The result shows that the average grain diameter of blank liposome is 145.8nm, polydispersity coefficient
PDI is 0.168, is less than 0.3, the average grain diameter of ergosterol liposome is 131.4nm, PDI 0.152, is less than 0.3, ergot
The average grain diameter of sterol combination with cisplatin Active loading liposome is 112.5, PDI 0.208, is less than 0.3, it is seen that the grain size of the two
Distribution is relatively concentrated.
3.1.5 Zeta potential measures
Under room temperature, ergosterol combination with cisplatin Active loading liposome is taken, dilutes 20 times, zeta potential instrument measures
Zeta potential.As a result the Zeta potential of blank liposome is -18.6mV, and the Zeta potential of ergosterol liposome is -23.4mV,
The Zeta potential of ergosterol combination with cisplatin Active loading liposome is -5.42mV, and liposome is negatively charged.
3.1.6 pH value measures
Under room temperature, ergosterol combination with cisplatin Active loading liposome is taken, after dilution, pH value is measured with acidometer.
The mean ph value for measuring 3 batches of samples is 6.64.
3.1.7 the measurement of ergosterol combination with cisplatin Active loading liposome peroxidation value (POV)
Contain unsaturated fatty acid chain, unstable chemcial property in phospholipid molecule, oxidizable hydrolysis makes membrane fluidity drop
Low, drug leakage is accelerated, and generates Peroxidation Product, such as malonaldehyde, aliphatic acid, can generate toxicity to human body.Malonaldehyde (MDA)
There can be absorption at 535nm with thiobarbituric acid reaction, the red product (TBA-pigment) of generation in acid condition,
Mda content can be obtained by measuring its absorption value, so as to investigate the degree of oxidation of phosphatide.This experiment is surveyed using malonaldehyde
Determine the degree of oxidation that method investigates liposome.
Precision draws liposome 1mL, is placed in 10mL centrifuge tubes, and TTH test solutions (thio bar of ratio of trichloroacetic acid 30g, 2- is added
0.25molL is added in appropriate acid 0.75g-1Hydrochloric acid 200mL is warmed to dissolving, is filtered after letting cool) 5mL, mixing sets 100 DEG C of water-baths
Heating 30min, is cooled to room temperature, addition 4.0mL TTH test solutions, with 4000rpmmin after mixing-1Centrifuge 10min.In absorption
Clear liquid measures absorbance value at 535nm wavelength, is denoted as peroxide value using TTH test solutions as blank control.3 lot sample of parallel determination
Product, average peroxide value are 0.1095 (table 7).
7 liposome peroxidation value result (POV) of table
3.1.8 dissolution test
Due to fat-soluble relatively strong, the solubility very little in dissolution medium of ergosterol, therefore water is only investigated in this experiment
The release of soluble drug cis-platinum.It is accurate respectively to draw ergosterol combination with cisplatin Active loading liposome 1mL and cis-platinum raw material
Drug solns 1mL, is placed in bag filter, and both ends are clamped with dialysis clamp.Since cis-platinum is unstable in the solution of no sodium or low sodium, easily
It is hydrolyzed into no anti-platinum of anticancer action component, therefore dissolution medium selects 100 times of 0.9%NaCl solution, is placed in water bath with thermostatic control oscillation
In device, shaking rate is 100rpmmin-1, release temperature is 37 DEG C, respectively at the 0.5th, 1,2,3,4,6,8,10,12, for 24 hours
Dialyzate 1mL is drawn, and supplements the 0.9%NaCl Fresh dialysate media of 37 DEG C of 1mL.Each sample point sample is used 0.45 μm
Filtering with microporous membrane after sample introduction is analyzed.By HPLC sample introductions, peak area is measured, equation of linear regression is substituted into and calculates each sample point
The drug release concentration of lower cis-platinum, is calculated as c1, the total dose of cis-platinum is denoted as M0。
It is calculated according to following formula：
Wherein, c1For the concentration that cis-platinum in each sample point discharges, V0For dissolution medium volume, V is sample volume, M0For wheat
The cis-platinum total amount contained in the sterol combination with cisplatin Active loading liposome of angle.《Chinese Pharmacopoeia annex rules of preparations》About liposome
The requirement of burst effect：The burst size for starting 0.5h answers≤40%, which meets
The requirement, and cumulative release percentage for 24 hours is more than 80%, is met the requirements (Fig. 2).
Four, ergosterol combination with cisplatin Active loading liposome cellular uptake is tested
It is quantitative to mix prepared ergosterol combination with cisplatin Active loading liposome with 1640 culture mediums (commercially available), make
The extension rate obtained finally is 64,96,128.A549 cells (commercially available, life science institute of Chinese Academy of Sciences cell bank) are connect
Kind is in 6 orifice plates, when cell fusion is to 80%, after old culture medium will be sucked out, and ergosterol combination with cisplatin Active loading lipid
The mixed liquor of body and culture medium, in 37 DEG C, 5%CO2Culture medium is sucked out after being incubated 2h in incubator, is rinsed 3 times with PBS, pancreas
Cell is collected in enzymic digestion, and PBS is added and washes 3 times, and centrifugation removal supernatant is eventually adding 0.5mL PBS and cell is resuspended, using BD streamings
Cell instrument detects intake intensity of the cell to the co-modified liposome of different dosing concentration.The results are shown in Table 8, by the result shows that, give
Ergosterol combination with cisplatin Active loading liposome is given, with the increase of extension rate, cellular uptake rate decreases.
8 ergosterol combination with cisplatin Active loading liposome cellular uptake of table
Five, the outer cell inhibitory effect experiment of ergosterol combination with cisplatin Active loading Via Liposomes
This experiment is in order to verify ergosterol, cis-platinum bulk pharmaceutical chemicals are prepared into after Liposomal formulation can enhance its antitumor work
Property, using in vitro culture A549 lung carcinoma cells, give ergosterol, cis-platinum, ergosterol combination with cisplatin bulk pharmaceutical chemicals and ergot
After the stimulation of sterol combination with cisplatin Active loading Liposomal formulation, the cell proliferation inhibition rate after various concentration administration is measured, and count
Calculate half inhibiting rate IC of the Liposomal formulation to A549 cells50Value.
Logarithmic growth phase A549 cells, adjustment cell is 1 × 10 after pancreatin digestion5A mL-1.100 μ are added with every hole
L is inoculated in 96 well culture plates, in 37 DEG C, 5%CO2It is cultivated in incubator, agent-feeding treatment after cell fusion is to 80%.It is added not
With the ergosterol combination with cisplatin Active loading liposome of extension rate and corresponding ergosterol, cis-platinum, ergosterol joint
Cis-platinum raw material medicine solution, while Normal group is set.Each 5 multiple holes of setting of each concentration, the carries out afterwards for 24 hours after dosing
MTT is detected.MTT (5mgmL are added per hole-1) solution 20 μ L, 37 DEG C, 5%CO2In incubator be incubated 4h after, with microplate reader in
Each hole absorbance (OD) value is measured at 492nm.Parallel 3 measurement of this experiment.
Fig. 3 finds out, drug effect for 24 hours when, when extension rate is 64,128,256 times, ergot steroid under identical extension rate
For alcohol combination with cisplatin Active loading liposome group compared with other three groups, inhibiting rate is significantly raised, and difference has pole conspicuousness, * * P<
0.01 (n=3).The IC of ergosterol cisplatin liposome administration50Value is 2.178+0.544 μ gmL-1.Illustrate, by ergosterol
And after cis-platinum is prepared into Liposomal formulation, it notable can must increase its external effect of anti-lung cancer.
Above-mentioned embodiment is only a preferred solution of the present invention, not the present invention is made in any form
Limitation, on the premise of not exceeding the technical scheme recorded in the claims also other variations and modifications.
Claims (8)
1. a kind of preparation method of ergosterol combination with cisplatin Active loading liposome, which is characterized in that include the following steps：
(1) ergosterol liposome preparation：Weigh lecithin, cholesterol, ergosterol, be added chloroform dissolving, rotary evaporation at
Film, vacuum drying are that hydrating fluid carries out aquation using ammonium chloride solution, and ultrasonic demoulding is popped one's head under ice bath and is ultrasonically treated, filters,
High pressure squeezes out to obtain ergosterol liposome；
Wherein, the raw material components of ergosterol liposome are matched as follows in terms of summation 100%：Ergosterol 8-15wt%, surplus
For lecithin and cholesterol, the molar ratio of lecithin and cholesterol is 3: 1-6: 1；
(2) ammonium chloride gradient is formed：Ergosterol liposome is added in the bag filter that molecular cut off is 8000-14000Da,
Bag filter is closed, the 2h that dialyses is put into distilled water, replaces first water, continues the 2h that dialyses；
(3) medicine is carried：Cis-platinum is mixed and made into cisplatin solution with water, and it is molten that cis-platinum is added in the ergosterol liposome after previous step is dialysed
Liquid is incubated, and the addition of ergosterol liposome is calculated with meeting the mass ratio of ergosterol and cis-platinum for 1: 1-4: 1, is incubated
40-60 DEG C of temperature is educated, incubation time 5-40min obtains product after incubation.
2. preparation method according to claim 1, it is characterised in that：The raw material group of ergosterol liposome in step (1)
Divide the proportioning in terms of summation 100% as follows：Ergosterol 10wt%, surplus are lecithin and cholesterol, lecithin and cholesterol
Molar ratio is 5: 1.
3. preparation method according to claim 1 or 2, it is characterised in that：The parameter that Probe Ultrasonic Searching is handled in step (1)
For：Ultrasonic time 20min, ultrasonic 2s, stop 1s, ultrasonic power 900W, and the pressure that high pressure squeezes out is 400-500psi.
4. preparation method according to claim 1 or 2, it is characterised in that：Cisplatin solution is a concentration of described in step (3)
0.03-0.3mg/mL。
5. preparation method according to claim 4, it is characterised in that：Cisplatin solution is a concentration of described in step (3)
0.15mg/mL。
6. preparation method according to claim 1 or 2, it is characterised in that：50 DEG C of incubation temperature in step (3), when incubation
Between 10min.
7. preparation method according to claim 1 or 2, it is characterised in that：The addition of ergosterol liposome in step (3)
Amount is 2.5: 1 calculating with the mass ratio for meeting ergosterol and cis-platinum.
8. preparation method according to claim 1 or 2, it is characterised in that：Ammonium chloride solution is a concentration of in step (1)
0.1-1.5mmol·L-1。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610141194.6A CN105816479B (en) | 2016-03-11 | 2016-03-11 | A kind of preparation method of ergosterol combination with cisplatin Active loading liposome |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610141194.6A CN105816479B (en) | 2016-03-11 | 2016-03-11 | A kind of preparation method of ergosterol combination with cisplatin Active loading liposome |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105816479A CN105816479A (en) | 2016-08-03 |
| CN105816479B true CN105816479B (en) | 2018-09-07 |
Family
ID=56987217
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610141194.6A Active CN105816479B (en) | 2016-03-11 | 2016-03-11 | A kind of preparation method of ergosterol combination with cisplatin Active loading liposome |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105816479B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11123353B2 (en) * | 2019-08-12 | 2021-09-21 | Zhejiang Chinese Medical University | Uses of ergosterol combined with gefitinib, preparation methods of liposome and freeze-dried powder thereof |
| CN110623928B (en) * | 2019-08-12 | 2021-12-10 | 浙江中医药大学 | Preparation method of ergosterol and gefitinib combined liposome |
| CN112618491A (en) * | 2020-12-22 | 2021-04-09 | 杭州市红十字会医院 | Preparation method of ergosterol and afatinib combined liposome |
| CN112603896B (en) * | 2020-12-22 | 2023-02-03 | 杭州市红十字会医院 | Preparation method of RGD cyclopeptide/R8 peptide modified ERG combined Afa double drug-loaded liposome freeze-dried powder |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007064658A2 (en) * | 2005-11-30 | 2007-06-07 | Transave, Inc. | Safe and effective methods of administering therapeutic agents |
-
2016
- 2016-03-11 CN CN201610141194.6A patent/CN105816479B/en active Active
Non-Patent Citations (3)
| Title |
|---|
| Concentration- and time-dependence of amphotericin-B induced permeability changes across ergosterol-containing liposomes;B. Eleazar Cohen等;《Biochimica et Biophysica Acta》;19861231;第857卷;第117-122页 * |
| 主动载药法制备两亲性药物脂质体的研究进展;苗彩云等;《中国医药工业杂志》;20051231;第36卷(第7期);第433-437页 * |
| 载顺铂转铁蛋白长循环脂质体对肺癌A549小鼠移植瘤的抑制作用;黄静等;《同济大学学报（医学版）》;20130228;第34卷(第1期);第13-16页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105816479A (en) | 2016-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105796593B (en) | A kind of RGD peptide and the co-modified ergosterol combination with cisplatin Active loading liposomes of cell-penetrating peptide R8 | |
| CN105796592B (en) | A kind of preparation method of RGD peptide and the co-modified ergosterol combination with cisplatin Active loading liposomes of cell-penetrating peptide R8 | |
| CN105816479B (en) | A kind of preparation method of ergosterol combination with cisplatin Active loading liposome | |
| CN105663159B (en) | A kind of ergosterol combination with cisplatin Active loading liposome and application thereof | |
| CN108379228A (en) | A kind of albumin nanoparticle and its preparation method and application of package pharmacological active substance | |
| CN106349193B (en) | Taxanes dimer, preparation method and its preparation | |
| CN102133190A (en) | Transferrin nanoparticles and preparation method and application thereof | |
| CN105669964A (en) | Ovarian cancer specifically targeted biodegradable amphiphilic polymer, polymer vesicle prepared from same and application of amphiphilic polymer | |
| CN107019673A (en) | A kind of Paclitaxel liposome preparation with tumor-targeting function and its preparation method and application | |
| CN110251464A (en) | A kind of compound liposome of Docetaxel and its preparation method and application | |
| CN103864921B (en) | Folic acid adriamycin immune formulation of dual-target treating cancer and preparation method thereof | |
| CN105287383A (en) | Application of novel liposome-entrapped mitoxantrone combined chemotherapeutic drug in antineoplastic treatment | |
| CN110054660A (en) | A kind of preparation and application of the breast cancer targeting lipids material of fructose modification | |
| CN108619094A (en) | A kind of nanometer formulation and preparation method thereof of anticancer natural product gambogicacid | |
| CN106883404A (en) | TPGS derivative and its preparation method and application | |
| CN109528654A (en) | A kind of irinotecan hydrochloride and doxorubicin hydrochloride carry liposome and preparation method thereof altogether | |
| CN108148193A (en) | A kind of liposome of high molecular material and its modification containing cholic acid | |
| CN104826118A (en) | Application of lipid-modified substance of chlorogenic acid and derivative thereof | |
| CN105380906B (en) | A kind of Cabazitaxel cancer target lipidosome injection and preparation method thereof | |
| CN101584661B (en) | Preparation of sorafenib self-microemulsifying drug delivery system for oral administration or intravenous injection and use thereof | |
| CN106420604A (en) | A kind of nano suspension of kind of litchi element class medicine and preparation method thereof | |
| CN108888774A (en) | A kind of Celastrol-dendrimer conjugate and the preparation method and application thereof | |
| CN104225612A (en) | Preparation and applications of oral absorption enhancer built based on natural P-glycoprotein inhibitor | |
| CN107441505A (en) | A kind of target magnetic nano liposome and preparation method thereof | |
| CN107929261A (en) | Targeted nano granule preparation of pH sensitivities a kind of of load chemotherapeutics and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |